BFM
PALI icon

Boothbay Fund Management’s Palisade Bio PALI Stock Holding History

Boothbay Fund Management’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$914K Buy
437,137
+267,489
+158% +$526K 0.01% 1148
2026
Q1 		$297K Buy
169,648
+37,000
+28% +$67.3K ﹤0.01% 1614
2025
Q4 		$312K Buy
+132,648
New +$255K ﹤0.01% 1402

Other funds holding PALI

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Boothbay Fund Management's PALI Position: Q2 2026 in Review

Boothbay Fund Management increased its Palisade Bio (PALI) stake by 158% in Q2 2026, buying an estimated $526K and bringing the position to 437,137 shares worth $914K. The position accounts for 0.01% of the portfolio, ranked #1148.

Boothbay Fund Management first reported a position in PALI in Q4 2025 and has held it in 3 quarters since. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • Boothbay Fund Management held 437,137 shares of Palisade Bio worth $914K as of Q2 2026.
  • Boothbay Fund Management bought 267,489 Palisade Bio shares in Q2 2026, an estimated $526K.
  • Palisade Bio made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1148 holding.
  • Boothbay Fund Management first reported a position in Palisade Bio in Q4 2025 and has held it in 3 quarters since.
  • 124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.